Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InflamEx: Continuous exercise with insulin degludec in type 1 diabetes
2017-000922-37Phase 4Completed
- Sponsor
- Medical University of Graz
- Start
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of insulin degludec in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Medical University of Graz. Primary endpoint: Difference in mean time in euglycemia 24 hours after exercise. Started Apr 2017; status: completed.
02
Drugs
insulin degludec
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2017-000922-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000922-37.